This study is in progress, not accepting new patients
A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease
Crohn's Disease (CD) Crohn's Disease Efficacy Safety Tolerability ABT-494 Crohn Disease Upadacitinib Upadacitinib (ABT-494) Dose A Upadacitinib (ABT-494) Dose B
Lead Scientist at UCSF
- Jonathan Terdiman
Dr. Jonathan P. Terdiman is a Professor of Clinical Medicine and Surgery and the Chief of the Gastroenterology Division at UCSF. He earned his undergraduate degree from Princeton University in 1985 and his medical degree from the Columbia University College of Physicians and Surgeons in 1989.
- in progress, not accepting new patients
- Start Date
- Completion Date
- This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses.
- Phase 2
- Study Type
- Last Updated